TMC207-TiDP13-C110: Interaction Study With Lopinavir/Ritonavir in Healthy Volunteer
NCT00828529 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 16
Last updated 2012-08-15
Summary
The purpose of this Phase I, open-label, randomized crossover trial is to investigate the pharmacokinetic interaction between steady-state lopinavir/ritonavir and single-dose TMC207 in healthy volunteers.
Conditions
Interventions
- DRUG
-
TMC207
Sponsors & Collaborators
-
Tibotec BVBA
lead INDUSTRY
Principal Investigators
-
Tibotec-Virco Virology BVBA Clinical Trial · Tibotec BVBA
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- CROSSOVER
Eligibility
- Min Age
- 18 Years
- Max Age
- 55 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2009-02-28
- Primary Completion
- 2009-05-31
- Completion
- 2009-05-31
More Related Trials
-
Safety and Antiviral Activity of TPV in HCV and/or HBV HIV Coinfected Patients TDM Randomised Pilot Evaluation
NCT00447902 ·Status: TERMINATED ·Phase: PHASE3
-
Study of Lopinavir/Ritonavir Tablets Versus Soft Gel Capsules and Once Daily Versus Twice Daily Administration, When Coadministered With Nucleoside Reverse Transcriptase Inhibitors in Antiretroviral Naive Human Immunodeficiency Virus Type 1 Infected Subjects
NCT00262522 ·Status: COMPLETED ·Phase: PHASE3
-
TMC114-C202: A Study of Safety, Efficacy, and Tolerability of TMC114 and Low Dose Ritonavir in HIV-1 Infected Patients
NCT00071097 ·Status: COMPLETED ·Phase: PHASE2
-
Pharmacokinetics (PK) and Safety of 2 Different Doses of Lopinavir/Ritonavir in in HIV/Tuberculosis (TB) Co-infected Patients Receiving Rifampicin Containing Anti-tuberculosis Therapy
NCT01138202 ·Status: COMPLETED ·Phase: PHASE2
-
Drug Interaction Study Between Eltrombopag and Lopinavir/Ritonavir in Healthy Adult Subjects.
NCT00833378 ·Status: COMPLETED ·Phase: PHASE1
-
A Randomised Trial to Evaluate the Antiviral Efficacy and Safety of Treatment With 500 mg Tipranavir (TPV) Plus 100 mg or 200 mg Ritonavir (RTV) p.o. BID in Comparison to 400 mg Lopinavir (LPV) Plus 100 mg RTV p.o. BID in Combination With Standard Background Regimen in ARV Therapy naïve Patients.
NCT00144105 ·Status: TERMINATED ·Phase: PHASE2
-
Effects of Tipranavir (TPV) and Ritonavir (RTV) on the Pharmacokinetic Characteristics of Tenofovir Disoproxil Fumarate in Healthy Volunteers
NCT02251145 ·Status: COMPLETED ·Phase: PHASE1
-
Tipranavir/Ritonavir Low Dose Pharmacokinetics in Treatment Naive Patients
NCT00530920 ·Status: COMPLETED ·Phase: PHASE2
-
Study of Lopinavir/Ritonavir Tablets Comparing Once-Daily Versus Twice-Daily Administration When Coadministered With Nucleoside/Nucleotide Reverse Transcriptase Inhibitors in Antiretroviral-Experienced Human Immunodeficiency Virus Type 1 Infected Subjects
NCT00358917 ·Status: COMPLETED ·Phase: PHASE3
-
Comparison of Two Dosing Regimens of GW433908/Ritonavir Versus Lopinavir/Ritonavir for 48 Weeks in HIV Patients Who Have Taken Protease Inhibitors and Experienced Virological Failure
NCT00025727 ·Status: UNKNOWN ·Phase: PHASE3
-
Drug Interaction Study Between GSK1349572 and Tipranavir/Ritonavir in Healthy Volunteers
NCT01068925 ·Status: COMPLETED ·Phase: PHASE1
-
A Study of the Pharmacokinetic and Pharmacodynamic Interactions Between Bictegravir, Tenofovir Alafenamide and Rifapentine in Healthy Adult Subjects
NCT04551573 ·Status: WITHDRAWN ·Phase: PHASE4
-
TMC114-TiDP3-C182 - A Study to Compare the Oral Bioavailability of a 800 mg Prototype Tablet Formulation of Darunivar (DRV) to That of the 400 mg Commercial Tablet Formulation in the Presence of Low Dose Ritonavir, Under Fasted and Fed Conditions
NCT01052883 ·Status: COMPLETED ·Phase: PHASE1
-
Safety Study of Tipranavir Co-administered With Low-dose Ritonavir (TPV/r) in Patients With Advanced HIV-1 Infection and Limited Treatment Options
NCT00144287 ·Status: COMPLETED ·Phase: PHASE3
-
Study of Lopinavir, Ritonavir, Tenofovir and Emtricitabine in HIV-Infected Antiretroviral Naïve Subjects
NCT00043966 ·Status: COMPLETED ·Phase: PHASE3
-
TMC114-C211: Trial of an Investigational Protease Inhibitor TMC114 With Ritonavir ("TMC114/r") in HIV-1 Infected Patients Who Have Never Been Treated With Antiretroviral Medications.
NCT00258557 ·Status: COMPLETED ·Phase: PHASE3
-
Clinical Experimentation With Tenofovir Disoproxyl Fumarate and Emtricitabine for COVID-19
NCT04712357 ·Status: UNKNOWN ·Phase: NA
-
An Evaluation of the Pharmacological Interaction of Lopinavir/r and Rifampin
NCT00771498 ·Status: COMPLETED ·Phase: PHASE4
-
Study Comparing Lopinavir/Ritonavir (LPV/r) + Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) With a Nucleoside Sparing Regimen Consisting of Lopinavir/Ritonavir + Raltegravir (RAL)
NCT00711009 ·Status: COMPLETED ·Phase: PHASE3
-
GSK1349572 Drug Interaction With Etravirine and Either Darunavir/Ritonavir or Lopinavir/Ritonavir
NCT00867152 ·Status: COMPLETED ·Phase: PHASE1
-
TMC278-TiDP6-C153 - A Study in Healthy Volunteers Investigating the Pharmacokinetic Interaction Between TMC278 and Raltegravir
NCT01288755 ·Status: COMPLETED ·Phase: PHASE1
-
Dual Boosted - Protease Inhibitor (PI) Pharmacokinetics (PK) Trial (Tipranavir / Ritonavir) in Highly Treatment-experienced HIV-1 Infected Patients
NCT00056641 ·Status: COMPLETED ·Phase: PHASE2
-
Safety and Acceptability Study of Non-occupational Prophylaxis (PEP) Following Potential Exposure to HIV
NCT01602822 ·Status: TERMINATED ·Phase: PHASE4
-
TMC114-C214: Trial of TMC114 Administered With Low Dose Ritonavir (RTV) in HIV-1 Infected Treatment Experienced Patients
NCT00110877 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Determine the Antiviral Activity of TMC310911 When Administered With Ritonavir in Treatment-Naive Human Immunodeficiency Virus - Type 1 (HIV-1) Infected Patients
NCT00838162 ·Status: COMPLETED ·Phase: PHASE2